Managing Tardive Dyskinesia in Long-term Care

CE / CME

Identification and Management of Tardive Dyskinesia: Best Practices to Promote Real-world Practice Change in the Long-term Care Setting

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: September 18, 2024

Expiration: September 17, 2025

Sanjay Gupta
Sanjay Gupta, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How knowledgeable do you feel regarding the safety profile of VMAT2 inhibitors in older patients?

2.

The gold standard for assessing and monitoring TD is:

3.

Which adverse events are most frequently seen with VMAT2 inhibitor treatment?

4.

A patient currently treated with a second-generation antipsychotic has developed noticeable symptoms of TD. Which VMAT2 inhibitor(s) is/are FDA approved to treat his condition?